Do not enter: Biogen reps banned from D.C.-area neurology clinics over controversial Alzheimer's drug Aduhelm

Biogen has certainly faced an uphill battle trying to convince physicians to prescribe the drugmaker’s highly scrutinized Alzheimer’s drug Aduhelm. It doesn't make it any easier if clinics won’t even let the company's sales reps through the front door.

But that’s the case at the Neurology Center in Washington, D.C., which has gone so far as to ban Biogen employees from entering their seven office locations in response to the controversy shrouding the company’s new med.